RU2017141776A3 - - Google Patents

Download PDF

Info

Publication number
RU2017141776A3
RU2017141776A3 RU2017141776A RU2017141776A RU2017141776A3 RU 2017141776 A3 RU2017141776 A3 RU 2017141776A3 RU 2017141776 A RU2017141776 A RU 2017141776A RU 2017141776 A RU2017141776 A RU 2017141776A RU 2017141776 A3 RU2017141776 A3 RU 2017141776A3
Authority
RU
Russia
Application number
RU2017141776A
Other languages
Russian (ru)
Other versions
RU2017141776A (ru
RU2717835C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017141776A publication Critical patent/RU2017141776A/ru
Publication of RU2017141776A3 publication Critical patent/RU2017141776A3/ru
Application granted granted Critical
Publication of RU2717835C2 publication Critical patent/RU2717835C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/02—Carbamic acids; Salts of carbamic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2017141776A 2012-07-13 2013-03-07 Способ лечения андроген-рецептор(ar)-положительных форм рака молочной железы с использованием селективных модуляторов андрогенных рецепторов (sarm) RU2717835C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261671366P 2012-07-13 2012-07-13
US61/671,366 2012-07-13
US201261726274P 2012-11-14 2012-11-14
US61/726,274 2012-11-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015104780A Division RU2648959C2 (ru) 2012-07-13 2013-03-07 Способ лечения андроген-рецептора(ar)-положительных форм рака молочной железы с использованием селективных модуляторов андрогенных рецепторов(sarm)

Publications (3)

Publication Number Publication Date
RU2017141776A RU2017141776A (ru) 2019-02-13
RU2017141776A3 true RU2017141776A3 (OSRAM) 2019-02-13
RU2717835C2 RU2717835C2 (ru) 2020-03-26

Family

ID=49914508

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2017141776A RU2717835C2 (ru) 2012-07-13 2013-03-07 Способ лечения андроген-рецептор(ar)-положительных форм рака молочной железы с использованием селективных модуляторов андрогенных рецепторов (sarm)
RU2015104780A RU2648959C2 (ru) 2012-07-13 2013-03-07 Способ лечения андроген-рецептора(ar)-положительных форм рака молочной железы с использованием селективных модуляторов андрогенных рецепторов(sarm)

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015104780A RU2648959C2 (ru) 2012-07-13 2013-03-07 Способ лечения андроген-рецептора(ar)-положительных форм рака молочной железы с использованием селективных модуляторов андрогенных рецепторов(sarm)

Country Status (20)

Country Link
US (1) US9604916B2 (OSRAM)
EP (2) EP3733170A1 (OSRAM)
JP (3) JP6226978B2 (OSRAM)
KR (2) KR102122941B1 (OSRAM)
CN (3) CN110840870A (OSRAM)
AU (3) AU2013203600C1 (OSRAM)
CA (1) CA2879049C (OSRAM)
CY (1) CY1123542T1 (OSRAM)
DK (1) DK2872482T3 (OSRAM)
ES (1) ES2818915T3 (OSRAM)
HR (1) HRP20201463T1 (OSRAM)
HU (1) HUE052574T2 (OSRAM)
IL (1) IL236681B (OSRAM)
IN (1) IN2015DN01046A (OSRAM)
LT (1) LT2872482T (OSRAM)
MX (2) MX375256B (OSRAM)
PL (1) PL2872482T3 (OSRAM)
PT (1) PT2872482T (OSRAM)
RU (2) RU2717835C2 (OSRAM)
WO (1) WO2014011220A2 (OSRAM)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
JP5449775B2 (ja) 2005-10-19 2014-03-19 チャバフ ピーティーワイ エルティーディー 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
CN110840870A (zh) 2012-07-13 2020-02-28 Gtx公司 选择性雄激素受体调节剂在治疗转移性和难治性乳癌中的应用
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
JP5958483B2 (ja) * 2013-07-31 2016-08-02 株式会社村田製作所 電力増幅モジュール
CN106999453A (zh) * 2014-10-16 2017-08-01 Gtx公司 使用sarm治疗泌尿病症的方法
CA2965372C (en) 2014-10-22 2023-09-05 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
WO2016141458A1 (en) 2015-03-12 2016-09-15 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
SI3283058T1 (sl) * 2015-04-16 2023-03-31 Novartis Ag Tableta ribocikliba
US10314797B2 (en) * 2016-06-10 2019-06-11 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
CN107735085B (zh) 2015-04-21 2021-05-14 Gtx公司 选择性雄激素受体降解剂(sard)配体和其使用方法
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
RU2019115778A (ru) * 2015-04-21 2019-06-24 Джи Ти Икс, ИНК. Селективные лиганды - разрушители андрогенных рецепторов (sard) и способы их применения
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US10035763B2 (en) 2015-04-21 2018-07-31 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10017471B2 (en) 2015-04-21 2018-07-10 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US9834507B2 (en) 2015-04-21 2017-12-05 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
SG11201803260PA (en) 2015-10-22 2018-05-30 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
RU2738646C2 (ru) 2016-04-01 2020-12-15 РЕКЬЮРИУМ АйПи ХОЛДИНГС, ЛЛС Модуляторы эстрогеновых рецепторов
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806719B2 (en) 2016-06-10 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
MX392531B (es) * 2017-06-29 2025-03-24 G1 Therapeutics Inc Formas morficas de g1t38 y metodos de preparacion de las mismas.
MX2020012066A (es) 2018-05-14 2021-04-28 Nuvation Bio Inc Compuestos anticancerígenos dirigidos a los receptores hormonales nucleares.
WO2019226991A1 (en) 2018-05-25 2019-11-28 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
US12202815B2 (en) 2018-09-05 2025-01-21 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
CN109761778A (zh) * 2018-12-10 2019-05-17 石家庄市度智医药科技有限公司 一种合成光学活性α-羟基丙酰胺衍生物的方法
US12109179B2 (en) 2019-03-28 2024-10-08 Essa Pharma Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
AU2020248105A1 (en) * 2019-03-28 2021-11-11 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
WO2020205608A1 (en) * 2019-03-29 2020-10-08 Emory University Uses of androgen receptor antagonists and jnk pathway inhibitors, and pharmaceutical compositions related thereto
MX2021013774A (es) 2019-05-14 2021-12-10 Nuvation Bio Inc Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares.
EP3976577A4 (en) * 2019-05-29 2023-06-28 University of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
CN119970752A (zh) 2019-06-03 2025-05-13 哈瓦赫治疗有限公司 用于递送雄激素剂和芳香酶抑制剂的药物制剂
AU2020326691A1 (en) 2019-08-06 2022-03-03 Recurium Ip Holdings, Llc Estrogen receptor modulators for treating mutants
CA3173036A1 (en) * 2020-02-25 2021-09-02 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
US20210323931A1 (en) 2020-04-17 2021-10-21 Essa Pharma, Inc. Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof
MX2022013391A (es) * 2020-04-24 2022-11-30 Astrazeneca Ab Pauta posologica para el tratamiento del cancer.
US20230172897A1 (en) * 2021-12-02 2023-06-08 Veru, Inc. Methods of treating breast cancers with selective androgen receptor modulators and additional therapeutic agents
WO2023172891A2 (en) * 2022-03-07 2023-09-14 Baylor College Of Medicine Biomarkers for combination therapy for er+ breast cancer
WO2023244059A1 (en) * 2022-06-15 2023-12-21 Ildong Pharmaceutical Co., Ltd. Methods of treating cancer using dual androgen receptor and pde5 inhibitor compounds
EP4637929A1 (en) * 2022-12-21 2025-10-29 Duke University Coadministration of estrogen with estrogen receptor modulator or degrader or er targeted protac for the treatment of estrogen responsive cancers

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3256096A (en) 1961-08-11 1966-06-14 Organic Nutrients Inc Anabolic stimulator as a poultry feed supplement
US3239345A (en) 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
US3949085A (en) 1970-05-27 1976-04-06 Chinoin Gyogyszer-Es Vegyeszeti Termakek Gyara Rt Anabolic-weight-gain promoting compositions containing isoflavone derivatives and method using same
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB1360001A (en) 1971-06-16 1974-07-17 Scherico Ltd Pharmaceutical compositions comprising substituted anilides
US3875229A (en) 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
US3865801A (en) 1973-06-15 1975-02-11 Atomic Energy Commission Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
US3946109A (en) 1973-08-08 1976-03-23 Ernst Kolb Animal feed composition containing certain vitamin combinations
US4036979A (en) 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
US4211781A (en) 1974-09-23 1980-07-08 Pfizer Inc. Process for the preparation of dustless quinoxaline-1,4-dioxide animal feed supplement premixes
US3991750A (en) 1975-04-28 1976-11-16 Syntex Corporation Dromostanolone propionate implant pellet useful for producing weight gains in animals and suppressing estrus in female animals
JPS6044294B2 (ja) 1976-04-15 1985-10-02 帝国臓器製薬株式会社 アニリド誘導体
US4139638A (en) 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
DE2862100D1 (en) 1977-10-12 1983-01-05 Ici Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en) 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
US4447421A (en) 1980-05-08 1984-05-08 American Cyanamid Company Process for the preparation of medicated animal feed supplement
NZ197008A (en) 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
JPS57171904A (en) 1981-04-15 1982-10-22 Mitsubishi Petrochem Co Ltd Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
US4670249A (en) 1985-04-12 1987-06-02 International Minerals & Chemical Corp. Growth-promoting compositions
US4837004A (en) 1985-10-18 1989-06-06 Eastman Kodak Company Rumen-stable pellets
US4904473A (en) 1986-06-23 1990-02-27 International Minerals & Chemical Corp. Ruminant feed antacid containing potassium, sodium and chlorine
GB8617653D0 (en) 1986-07-18 1986-08-28 Ici Plc Amide derivatives
GB8617652D0 (en) 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
US4849447A (en) 1987-10-13 1989-07-18 Pitman-Moore, Inc. Zearalanol derivatives with anabolic activity
JPH03502326A (ja) 1988-01-28 1991-05-30 ポリゲン　ホールディング　コーポレイション 成長ホルモン放出活性を有するポリペプチド化合物類
DE68922602T2 (de) 1988-01-28 1995-12-07 Polygen Holding Corp Polypeptide mit hormonwachstumsbefreiender wirkung.
US4977288A (en) 1988-01-29 1990-12-11 President And Fellows Of Harvard College M-aminophenyltrialkylstannane
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5179080A (en) 1989-08-31 1993-01-12 Clinical Homecare, Corp. Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease
KR100221066B1 (ko) 1989-10-13 1999-10-01 스튜어트 엘.왓트 에리트로포이에틴 유사체와 그를 포함하는 제약학적 조성물
US5030657A (en) 1989-10-23 1991-07-09 University Of Georgia Research Foundation, Inc. L-carnitine supplemented catfish diet
US5288496A (en) 1990-05-15 1994-02-22 Stolle Research & Development Corporation Growth promoters for animals
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
WO1995019770A1 (en) 1994-01-21 1995-07-27 Sepracor, Inc. Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US5609849A (en) 1994-03-11 1997-03-11 The Trustees Of The University Of Pennsylvania Serotonin (5-HT1A) receptor ligands and imaging agents
EP0683172B1 (en) 1994-05-19 1997-08-13 Akzo Nobel N.V. 11,21-Bisphenyl-19-norpregnane derivatives
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
WO1998005962A1 (en) 1996-08-02 1998-02-12 Panvera Corporation A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization
US20090264534A1 (en) 1996-11-27 2009-10-22 Dalton James T Selective androgen receptor modulators
US6492554B2 (en) 2000-08-24 2002-12-10 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US6071957A (en) 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US7205437B2 (en) 1996-11-27 2007-04-17 University Of Tennessee Research Foundation Selective androgen receptor modulators
US7759520B2 (en) 1996-11-27 2010-07-20 University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US6995284B2 (en) 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US20050038110A1 (en) 2000-08-24 2005-02-17 Steiner Mitchell S. Selective androgen receptor modulators and methods of use thereof
US7518013B2 (en) 2000-08-24 2009-04-14 University Of Tennessee Research Foundation Selective androgen receptor modulators
US5929058A (en) 1996-12-24 1999-07-27 Zymogenetics, Inc. Treatment agents and methods for treating type II diabetes and symptoms of type II diabetes
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
AU7604798A (en) 1997-05-30 1998-12-30 University Of Tennessee Research Corporation, The Non-steroidal agonist compounds and their use in male hormone therapy
US6019957A (en) 1997-06-04 2000-02-01 The University Of Tennessee Research Corporation Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
EP0903146A1 (en) 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
US6022137A (en) 1998-04-29 2000-02-08 Buckeye Feed Mills, Inc. Conditioner for processing raw grain composition to produce pelletized feed
ES2318899T3 (es) 1998-07-06 2009-05-01 Bristol-Myers Squibb Company Bifenil sulfonamidas como antagonistas duales de los receptores de angiotensina y endotelina.
ES2201822T3 (es) 1998-12-23 2004-03-16 G.D. Searle Llc Combinaciones de inhibididores de la proteina de transferencia de ester de colesterilo y de derivados de acido nicotinico para indicaciones cardiovasculares.
ES2226811T3 (es) 1999-03-29 2005-04-01 F. Hoffmann-La Roche Ag Activadores de glucoquinasa.
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6795776B1 (en) 1999-10-14 2004-09-21 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain
ATE350036T1 (de) 1999-10-14 2007-01-15 Kaken Pharma Co Ltd Tetrahydroquinolin-derivate
IL149056A0 (en) 1999-10-19 2002-11-10 Nobex Corp Methods of asymmetrically synthesizing enantiomers of casodex, its derivatives and intermediates thereof
NZ518552A (en) 1999-10-27 2003-10-31 Nobex Corp Resolution of intermediates in the synthesis of substantially pure bicalutamide
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
AU2625201A (en) 2000-01-03 2001-07-16 Ramot University Authority For Applied Research And Industrial Development Ltd. Glycogen synthase kinase-3 inhibitors
US6441197B1 (en) 2000-01-20 2002-08-27 Daiichi Pure Chemicals Co., Ltd. Diaminofluorescein derivative
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US7713989B2 (en) 2000-04-27 2010-05-11 Dow Robert L Glucocorticoid receptor modulators
CA2413417A1 (en) 2000-06-28 2002-01-03 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
US20020173495A1 (en) 2000-08-24 2002-11-21 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US6838484B2 (en) 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US7645898B2 (en) 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US8445534B2 (en) 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US20030232792A1 (en) 2000-08-24 2003-12-18 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US6998500B2 (en) 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
CA2420279C (en) 2000-08-24 2011-07-19 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20070173546A1 (en) 2000-08-24 2007-07-26 Dalton James T Selective androgen receptor modulators and method of use thereof
US7855229B2 (en) 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US8008348B2 (en) 2001-12-06 2011-08-30 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
US20040260108A1 (en) 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US20030229099A1 (en) 2000-08-30 2003-12-11 Zhu Hugh Y. Novel farnesyl protein transferase inhibitors as antitumor agents
US6777446B2 (en) 2000-09-05 2004-08-17 Tularik, Inc. FXR modulators
JPWO2002022585A1 (ja) 2000-09-14 2004-01-22 科研製薬株式会社 テトラヒドロキノリン化合物
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
JP2003137814A (ja) 2001-08-10 2003-05-14 Takeda Chem Ind Ltd ＧｎＲＨアゴニストの併用剤
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US20060004042A1 (en) 2001-08-23 2006-01-05 Dalton James T Formulations comprising selective androgen receptor modulators
DE60230687D1 (de) 2001-11-29 2009-02-12 Gtx Inc Verhinderung und Behandlung von durch Androgenmangel induzierter Osteoporose
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20070161608A1 (en) 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
DK1463497T3 (da) 2001-12-06 2012-01-30 Gtx Inc Behandling af muskelsvind med selektive androgenreceptormodulatorer
WO2003065983A2 (en) 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
HRP20100067A2 (hr) 2002-02-07 2010-04-30 University Of Tennessee Research Foundation Liječenje benigne hiperplazije prostate selektivnim modulatorima androgenih receptora
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
MXPA04009460A (es) 2002-02-28 2006-04-27 Univ Tennessee Res Foundation Moduladores receptores de androgeno selectivo multi-sustituidos y metodos de uso de los mismos.
US7705182B2 (en) 2002-02-28 2010-04-27 University Of Tennessee Research Foundation Multi-substituted selective androgen receptor modulators and methods of use thereof
HRP20040818A2 (en) 2002-02-28 2005-02-28 University Of Tennessee Research Foundation Haloacetamide and azide substituted compounds and methods of use thereof
US7803970B2 (en) 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
US7344700B2 (en) 2002-02-28 2008-03-18 University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
US7186838B2 (en) 2002-03-13 2007-03-06 Merck & Co., Inc. Fluorinated 4-azasteroid derivatives as androgen receptor modulators
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
EP1534663A4 (en) 2002-06-17 2006-08-30 Univ Tennessee Res Foundation N-BREAKDOWN SELECTIVE MODULATORS OF THE ANDROGEN RECEPTOR AND METHOD FOR THEIR USE
EP1398029A1 (en) 2002-09-10 2004-03-17 LION Bioscience AG NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
EP1562906A4 (en) 2002-10-15 2009-12-02 Univ Tennessee Res Foundation HETEROCYCLIC SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHOD FOR THEIR USE
US20040265916A1 (en) 2002-10-15 2004-12-30 Dalton James T. Method for detecting selective androgen receptor modulators
CN1726019A (zh) 2002-10-15 2006-01-25 Gtx公司 用选择性雄激素受体调节剂治疗肥胖症
US20040197928A1 (en) 2002-10-15 2004-10-07 Dalton James T. Method for detecting selective androgen receptor modulators
AU2003287077B2 (en) 2002-10-15 2007-09-20 University Of Tennessee Research Foundation Methylene-bridged selective androgen receptor modulators and methods of use thereof
US20040087810A1 (en) 2002-10-23 2004-05-06 Dalton James T. Irreversible selective androgen receptor modulators and methods of use thereof
US20140011774A1 (en) 2002-12-05 2014-01-09 University Of Tennessee Research Foundation Selective androgen receptor modulators
US8309603B2 (en) * 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
JP2006517807A (ja) 2002-12-30 2006-08-03 パーデュー・リサーチ・ファウンデーション 中枢神経系の損傷の治療方法
JP4603528B2 (ja) 2003-01-13 2010-12-22 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体の大規模合成
CA2513975A1 (en) * 2003-01-22 2004-08-12 Gtx Inc. A method of treating breast cancer with androgen receptor antagonists
WO2004064747A2 (en) 2003-01-22 2004-08-05 Gtx Inc. Treating androgen deficiency in female (adif)-associated conditions with sarms
US20040167103A1 (en) 2003-02-24 2004-08-26 Dalton James T. Haloacetamide and azide substituted compounds and methods of use thereof
GB0308335D0 (en) 2003-04-10 2003-05-14 Novartis Ag Organic compounds
CN1325506C (zh) 2003-05-15 2007-07-11 中国科学院上海药物研究所 骨重吸收抑制剂阿伦膦酸及生理可接受的盐和它的制备
EP1643971A2 (en) 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
FI20030958A0 (fi) 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
US7217720B2 (en) 2003-09-10 2007-05-15 Merck & Co., Inc. 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
CA2534314C (en) 2003-09-12 2012-11-13 Applied Research Systems Ars Holding N.V. Benzothiazole derivatives for the treatment of diabetes
AU2004281708B2 (en) 2003-10-14 2011-02-17 University Of Tennessee Research Foundation Treating bone-related disorders with selective androgen receptor modulators
TW200523235A (en) 2003-10-15 2005-07-16 Gtx Inc Anti-cancer compounds and methods of use thereof
US20050137172A1 (en) * 2003-10-15 2005-06-23 Dalton James T. Haloacetamide and azide substituted compounds and methods of use thereof
GB0325402D0 (en) 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
CA2522874A1 (en) 2003-12-16 2005-07-07 Gtx, Inc. Prodrugs of selective androgen receptor modulators and methods of use thereof
TW200530181A (en) 2004-01-13 2005-09-16 Bristol Myers Squibb Co Heterocyclic compounds useful as growth hormone secretagogues
SI1756096T1 (sl) 2004-05-03 2009-10-31 Hoffmann La Roche Indolilni derivati kot modulatorji jetrnega x receptorja
US20130034562A1 (en) 2004-06-07 2013-02-07 Dalton James T Selective androgen receptor modulators for treating diabetes
DK2289872T3 (en) 2004-06-07 2017-10-09 Univ Tennessee Res Found Medical use of a selective androgen receptor modulator
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
KR20070041560A (ko) 2004-07-14 2007-04-18 얀센 파마슈티카 엔.브이. 에스트로겐 관련 수용체-알파 매개 질병 치료를 위한아릴리덴
US7825229B2 (en) 2005-03-25 2010-11-02 Rosetta Genomics Ltd. Lung cancer-related nucleic acids
JP2009506119A (ja) 2005-08-31 2009-02-12 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置
CA2628259A1 (en) 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
US8796313B2 (en) 2005-11-01 2014-08-05 Janssen Pharmaceutica N.V. Substituted dihydroisoindolones as allosteric modulators of glucokinase
US8158828B2 (en) 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
EA018066B1 (ru) 2005-11-28 2013-05-30 Джи Ти Икс, ИНК. Агент, связывающийся с ядерными рецепторами
AU2006331770A1 (en) 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist
EP1801140A1 (en) 2005-12-22 2007-06-27 Mnemoscience GmbH Macro-diacrylate
US8168216B2 (en) * 2006-03-22 2012-05-01 Medigene Ag Treatment of triple receptor negative breast cancer
JP5215300B2 (ja) 2006-07-12 2013-06-19 ユニバーシティ オブ テネシー リサーチ ファウンデーション 置換アシルアニリドおよびそれらの使用方法
BRPI0714526A2 (pt) 2006-08-24 2013-04-30 Univ Tennessee Res Foundation acilanilidas substituÍdas e seus mÉtodos de uso
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9078888B2 (en) 2007-01-22 2015-07-14 Gtx, Inc. Nuclear receptor binding agents
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
AU2008298901C1 (en) 2007-09-11 2013-10-03 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
WO2011017687A1 (en) * 2009-08-06 2011-02-10 Ray Partha S Diagnosis of primary and metastatic basal-like breast cancer and other cancer types
MX2012004624A (es) * 2009-10-23 2012-08-23 Panacela Labs Inc Metodos para tratar canceres positivos para el receptor de androgenos.
CN103002737A (zh) 2010-01-11 2013-03-27 Gtx公司 治疗睑板腺功能障碍的方法
AR083916A1 (es) * 2010-11-18 2013-04-10 Takeda Pharmaceutical Metodo para tratar el cancer de mama y cancer de ovarios
CN110840870A (zh) 2012-07-13 2020-02-28 Gtx公司 选择性雄激素受体调节剂在治疗转移性和难治性乳癌中的应用
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)

Also Published As

Publication number Publication date
RU2648959C2 (ru) 2018-03-28
PT2872482T (pt) 2020-09-22
US20140018433A1 (en) 2014-01-16
DK2872482T3 (da) 2020-09-21
HRP20201463T1 (hr) 2021-04-02
AU2013203600A1 (en) 2014-01-30
KR20150038085A (ko) 2015-04-08
RU2015104780A (ru) 2016-08-27
JP2017101088A (ja) 2017-06-08
EP2872482B1 (en) 2020-07-08
JP6226978B2 (ja) 2017-11-08
KR102122941B1 (ko) 2020-06-15
US9604916B2 (en) 2017-03-28
CN108143728A (zh) 2018-06-12
EP3733170A1 (en) 2020-11-04
EP2872482A4 (en) 2016-03-30
CN110840870A (zh) 2020-02-28
RU2017141776A (ru) 2019-02-13
CN104754939A (zh) 2015-07-01
MX2015000572A (es) 2015-09-23
EP2872482A2 (en) 2015-05-20
JP6386120B2 (ja) 2018-09-05
CY1123542T1 (el) 2022-03-24
AU2013203600B2 (en) 2016-03-03
HUE052574T2 (hu) 2021-05-28
IN2015DN01046A (OSRAM) 2015-06-26
JP2015522069A (ja) 2015-08-03
AU2018201450B2 (en) 2019-06-13
IL236681A0 (en) 2015-02-26
AU2018201450A1 (en) 2018-03-22
KR102238970B1 (ko) 2021-04-09
MX2020009725A (es) 2020-10-08
JP6759290B2 (ja) 2020-09-23
WO2014011220A3 (en) 2015-03-05
CA2879049A1 (en) 2014-01-16
AU2016203696A1 (en) 2016-06-23
CA2879049C (en) 2021-02-23
JP2018168201A (ja) 2018-11-01
RU2717835C2 (ru) 2020-03-26
IL236681B (en) 2021-04-29
AU2013203600C1 (en) 2016-11-24
WO2014011220A2 (en) 2014-01-16
MX375256B (es) 2025-03-06
KR20200069394A (ko) 2020-06-16
PL2872482T3 (pl) 2021-03-08
ES2818915T3 (es) 2021-04-14
AU2016203696B2 (en) 2017-11-30
LT2872482T (lt) 2020-12-28

Similar Documents

Publication Publication Date Title
BR112014017635A2 (OSRAM)
BR112014017614A2 (OSRAM)
BR112014017625A2 (OSRAM)
BR112014017659A2 (OSRAM)
BR112014017592A2 (OSRAM)
BR112014017646A2 (OSRAM)
BR112014017607A2 (OSRAM)
BR112014017638A2 (OSRAM)
AR092201A1 (OSRAM)
BR112013027865A2 (OSRAM)
BR112014017609A2 (OSRAM)
BR112014017634A2 (OSRAM)
BR112014017644A2 (OSRAM)
BR112014017588A2 (OSRAM)
BR112014017618A2 (OSRAM)
BR112014017647A2 (OSRAM)
BR112014013184A8 (OSRAM)
BR112014017623A2 (OSRAM)
BR112014017652A2 (OSRAM)
BR112014017630A2 (OSRAM)
BR112014017627A2 (OSRAM)
BR112014017621A2 (OSRAM)
BR112014017631A2 (OSRAM)
BR112014017641A2 (OSRAM)
BR112014017622A2 (OSRAM)